BridgeBio Pharma Inc (BridgeBio) is a commercial-stage biopharmaceutical company that develops drugs for genetic diseases and cancer. The company’s pipeline products include precision cardiorenal, mendelian, precision oncology and gene therapy. Its precision cardiorenal and mendelian drugs include acoramidis, encaleret, fosdenopterin, low-dose infigratinib, BBP-418 and BBP-671. BridgeBio’s precision oncology and gene therapy drugs include high-dose infigratinib, BBO-8520, BBP-398, PI3Kα, BBP-954, Pan-KRAS inhibitor, BBP-812, BBP-631 and AAV gene therapy. The company's brands include TRUSELTIQ and NULIBRY. It works in partnership with academic partners and industrial partners. The company operates in Canada, the US, France, Germany, Switzerland and the UK, among others. BridgeBio is headquartered in Palo Alto, California, the US.
Headquarters
United States of America
Address
3160 Porter Dr., Suite 250, Palo Alto, California, 94304
Website
bridgebio.com
Telephone
1 650 3919740
No of Employees
392
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BBIO (NASD)
Revenue (2022)
$9.3M
-88%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-33.7%
(2022 vs 2021)
Market Cap*
$4.6B
Net Profit Margin (2022)
XYZ
-1,015.7%
(2022 vs 2021)
* As of and is in US$
BridgeBio Pharma Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | TRUSELTIQ |
| Precision Cardiorenal: | NULIBRY |
| Acoramidis: Tetrameric Transthyretin Amyloidosis | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Others | In February, the company's New Drug Application for acoramidis was accepted by the U.S. Food and Drug Administration for the treatment of ATTR-CM. |
| 2024 | Contracts/Agreements | In February, the company and Kyowa Kirin Co., Ltd entered into a partnership agreement, under the agreement, BridgeBio's affiliate, QED Therapeutics, granted Kyowa Kirin a license to develop and market infigratinib for the treatment of achondroplasia, hypochondroplasia, and other skeletal dysplasias in Japan. |
| 2024 | Contracts/Agreements | In January, the company entered into a partnership with Invitae to create new insights for genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs. |
Competitor Comparison
| Key Parameters | BridgeBio Pharma Inc | Pfizer Inc | Sanofi | BioMarin Pharmaceutical Inc | Neurocrine Biosciences Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | France | United States of America | United States of America |
| City | Palo Alto | New York | Paris | Novato | San Diego |
| State/Province | California | New York | Ile-de-France | California | California |
| No. of Employees | 392 | 88,000 | 87,994 | 3,401 | 1,400 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Neil Kumar, Ph.D. | Chief Executive Officer; Director | Executive Board | 2015 | 44 |
| Frank P. McCormick, Ph.D. | Director; Chairman - Oncology | Executive Board | 2023 | 72 |
| Charles Homcy, M.D. | Chairman - Pharmaceuticals; Director | Executive Board | 2019 | 74 |
| Brian Stephenson, Ph.D. | Secretary; Chief Financial Officer | Senior Management | 2018 | 42 |
| Josh Loehrer | Chief People Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward